Pediatric Clinical Trials Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Phase (Phase I, Phase II, Phase III, and Phase IV), Study Design (Treatment Studies and Observational Studies), Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas), By Region, and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationPediatric Clinical Trials Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Phase (Phase I, Phase II, Phase III, and Phase IV), Study Design (Treatment Studies and Observational Studies), Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas), By Region, and Competition
| Forecast Period | 2024-2028 |
| Market Size (2022) | 14.70 billion |
| CAGR (2023-2028) | 7.50% |
| Fastest Growing Segment | Treatment Studies |
| Largest Market | North America |
Market Overview
Global Pediatric Clinical Trials Market has valued at USD 14.70 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.50%
The prevalence of pediatric diseases, including rare diseases and chronic conditions, has been on the rise. This drives the need for clinical trials to develop effective treatments for children. Advances in genomics and molecular biology have led to the development of targeted therapies for pediatric diseases. These innovative treatments require clinical trials to assess their safety and efficacy. Many pediatric clinical trials focus on rare diseases, which are often underserved by traditional drug development. Orphan drug status and incentives provided by regulators have driven research in this area. Pediatric clinical trials are increasingly conducted on a global scale. This globalization allows for access to diverse patient populations, reducing the time required for patient recruitment and enhancing the generalizability of trial results. The availability of funding from government agencies, nonprofit organizations, and pharmaceutical companies has boosted pediatric clinical trial activity. These financial resources support research into pediatric treatments.
Key Market Drivers
Growing Focus on Rare Diseases
Rare diseases, also known as orphan diseases, often lack approved treatments or have limited therapeutic options. Many of these diseases affect children, and pediatric patients with rare diseases face particularly challenging health conditions. Pediatric clinical trials are essential to develop treatments for these underserved populations. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), offer incentives to encourage the development of orphan drugs for rare diseases. These incentives include extended market exclusivity, tax credits, and waived application fees, which make pediatric clinical trials more attractive to pharmaceutical companies. Rare diseases often receive orphan drug designation, which grants special status to drugs intended to treat rare conditions. This designation can expedite the drug development process and increase funding opportunities for pediatric clinical trials. Patient advocacy groups for rare diseases play a crucial role in raising awareness, supporting research, and facilitating clinical trials. They often collaborate with researchers, clinicians, and industry partners to drive pediatric clinical trial initiatives.
Advances in genomics and personalized medicine have increased the understanding of the genetic basis of many rare diseases. This knowledge allows for the development of targeted therapies, making pediatric clinical trials more focused and promising. Rare diseases are, by definition, rare, and patients may be dispersed globally. Collaborative efforts among researchers, healthcare providers, and pharmaceutical companies on an international scale help pool resources and access diverse patient populations for clinical trials. Pediatric research networks, such as the Pediatric Trials Network (PTN) and the International Rare Diseases Research Consortium (IRDiRC), focus on rare diseases. They facilitate research, data sharing, and the conduct of pediatric clinical trials in the rare disease field. The orphan drug market, including treatments for rare pediatric diseases, can be financially attractive for pharmaceutical companies. Developing effective treatments for rare diseases can lead to market exclusivity and premium pricing. Advances in biomedical research, including gene therapy, gene editing, and cell-based therapies, have opened new avenues for treating rare diseases. These cutting-edge approaches often require pediatric clinical trials to assess safety and efficacy. Successful pediatric clinical trials for rare diseases can have a profound and lasting impact on patients' lives. They offer the potential to improve or even save the lives of children who would otherwise have limited treatment options. This factor will help in the development of Global Pediatric Clinical Trials Market.
Advancements in Precision Medicine
The mapping of an individual's genome has become more accessible and cost-effective. Next-generation sequencing (NGS) technologies have revolutionized genomics, enabling the sequencing of entire genomes, exomes, and specific gene panels. This information is used to identify genetic mutations, variations, and susceptibilities to specific diseases. Pharmacogenomics studies how an individual's genetic makeup affects their response to drugs. By understanding genetic variations, healthcare providers can prescribe medications that are more likely to be effective and have fewer adverse effects for a particular patient. Precision oncology utilizes genomic profiling of tumors to identify specific genetic alterations that drive cancer growth. Targeted therapies and immunotherapies are designed to attack cancer cells based on their molecular characteristics, leading to more effective and less toxic treatments. Liquid biopsy techniques allow for the non-invasive detection of cancer and other diseases by analyzing genetic material (e.g., DNA, RNA) in bodily fluids like blood. This approach enables early cancer detection, monitoring treatment responses, and tracking disease progression. Single-cell sequencing technologies enable the study of individual cells within complex tissues. This is invaluable for understanding cell heterogeneity in diseases, such as cancer, and for developing personalized treatments. Epigenetics focuses on modifications to DNA that do not change the underlying genetic code but affect gene expression. Understanding epigenetic changes can provide insights into disease mechanisms and potential therapeutic targets.
AI and machine learning algorithms can analyze large-scale genomic and clinical data to identify patterns and predict disease risk, progression, and treatment responses. These tools aid in personalized treatment recommendations. Immunogenomics combines genomics and immunology to understand how an individual's immune system interacts with diseases. It is essential in developing personalized immunotherapies, such as CAR-T cell therapy for cancer. Genomic sequencing has improved the diagnosis of rare genetic diseases, many of which affect children. Identifying the genetic cause of these conditions can lead to more accurate diagnoses and potential treatments. Patients can contribute to their own precision medicine by providing data through wearable devices and mobile apps. This real-time data can be integrated with genetic and clinical information to personalize healthcare. Large-scale genomic studies help identify genetic risk factors for common diseases like heart disease, diabetes, and Alzheimer's. This knowledge can inform preventive measures and early interventions. As precision medicine advances, ethical considerations surrounding privacy, consent, and data sharing become increasingly important. Regulatory agencies are developing guidelines to ensure the responsible use of genomic and personalized data. This factor will pace up the demand of Global Pediatric Clinical Trials Market.
Increasing Pediatric Health Issues
Pediatric health issues, including chronic conditions, rare diseases, and developmental disorders, are on the rise globally. As the pediatric population grows, so does the number of children affected by these conditions, necessitating clinical research to develop effective treatments. Many pediatric diseases and conditions have limited or no approved treatments. Pediatric patients often face unmet medical needs, and clinical trials are crucial for developing new therapies that can improve their health and quality of life. Advances in genomics have increased our understanding of genetic and congenital disorders in children. This knowledge has opened new avenues for developing targeted therapies, personalized medicine, and gene-based treatments, all of which require clinical trials. Cancer is one of the leading causes of death among children. Pediatric oncology clinical trials are critical for developing more effective and less toxic treatments for childhood cancers.
Emerging infectious diseases and the ongoing threat of epidemics and pandemics, such as COVID-19, highlight the need for clinical trials to test vaccines and treatments for pediatric populations. Neurodevelopmental disorders, such as autism spectrum disorders and attention-deficit/hyperactivity disorder (ADHD), are increasingly prevalent. Clinical trials aim to develop interventions that can improve the lives of children with these conditions. Premature birth and neonatal health issues are significant concerns. Clinical trials in neonatology focus on improving outcomes for premature and critically ill newborns. The rising incidence of childhood obesity and related metabolic disorders necessitates research into interventions and treatments. Pediatric clinical trials play a role in addressing these health issues. Mental health issues in children, including anxiety, depression, and behavioral disorders, are receiving greater attention. Clinical trials aim to identify effective therapies and interventions. Various global health organizations and initiatives prioritize improving pediatric healthcare and access to essential medications. They support and fund clinical trials as part of their mission to address pediatric health challenges. This factor will accelerate the demand of Global Pediatric Clinical Trials Market.
Download Free Sample Report
Diversity and Representation
Clinical trial results need to be applicable to the entire population, including various demographic groups. Lack of diversity can lead to biased or incomplete findings that may not accurately reflect how a treatment will work in real-world settings, especially for underrepresented populations. Pediatric clinical trials that do not include diverse populations can perpetuate health disparities. Certain ethnic and racial groups may be disproportionately affected by certain diseases, and they should have the opportunity to benefit from advances in pediatric medicine. Genetic, physiological, and environmental factors can influence how treatments affect individuals. It's essential to understand how a drug or intervention works in diverse populations, including different age groups, genders, ethnicities, and socioeconomic backgrounds. Pediatric clinical trials require informed consent from parents or guardians. Ensuring that these caregivers have access to understandable information and that they represent diverse backgrounds is an ethical imperative. Regulatory agencies, such as the FDA and EMA, encourage or require the inclusion of diverse populations in clinical trials. Failure to meet these requirements can delay regulatory approvals. Engaging with diverse communities is essential for building trust and encouraging participation in clinical trials. Community partnerships can help identify barriers to participation and develop strategies to overcome them. Cultural factors can influence healthcare decision-making. Clinical trial protocols and recruitment strategies should be culturally sensitive to engage a broad range of participants.
Parental Concerns and Reluctance
Parents are naturally concerned about the safety of their children. They may worry about potential risks and adverse effects associated with the investigational treatments or interventions being tested in the trial. Insufficient information or understanding about the trial, its purpose, procedures, and potential benefits can lead to parental reluctance. Effective communication and providing clear, comprehensible information are critical. Some parents may perceive clinical trials as experimental and fear that their child will be treated like a "guinea pig." Addressing these misconceptions through education is essential. Parents may have ethical concerns, such as whether it is morally acceptable to enroll their child in a clinical trial, especially if they perceive a potential conflict between the child's well-being and the trial's goals. In randomized controlled trials, some children may receive a placebo or standard treatment instead of investigational therapy. Parents may be reluctant to enroll their child if they believe the child will receive a placebo. Participation in clinical trials often involves additional time, travel, and commitments. Parents may face logistical challenges, such as scheduling conflicts or the need for frequent clinic visits. Trust in healthcare providers and the research institution is crucial for parental willingness to enroll their child in a clinical trial. Any perceived lack of trustworthiness can deter participation. Language barriers and cultural differences can make it difficult for parents to fully understand the trial's details and make informed decisions. Culturally sensitive communication is essential.
Key Market Trends
Increasing Emphasis on Pediatric Drug Development
The pediatric drug market represents a significant opportunity for pharmaceutical companies. Developing medications specifically for children can lead to market exclusivity and premium pricing, incentivizing investment in pediatric drug development. Advances in pediatric healthcare and medicine have expanded the potential for drug development. Innovative therapies, precision medicine approaches, and genetic-based treatments offer new avenues for addressing pediatric diseases. Pediatric research networks and collaborations, such as the Pediatric Trials Network (PTN) and the International Neonatal Consortium (INC), facilitate pediatric drug development by bringing together expertise, resources, and patient populations. Patient advocacy groups and organizations dedicated to pediatric health play a crucial role in raising awareness about the importance of pediatric clinical trials and advocating for research in pediatric drug development. Various global health organizations and initiatives prioritize improving pediatric healthcare and access to essential medications, further driving the emphasis on pediatric drug development.
Segmental Insights
Phase Insights
In 2022, the Global Pediatric Clinical Trials Market dominated by phase II trials segment and is predicted to continue expanding over the coming years.
Study Design Insights
In 2022, the Global Pediatric Clinical Trials Market largest share was held by Treatment studies segment and is predicted to continue expanding over the coming years.
Therapeutic Areas Insights
In 2022, the Global Pediatric Clinical Trials Market largest share was held by oncology segment in the forecast period and is predicted to continue expanding over the coming years.
Regional Insights
The North America region dominates the Global Pediatric Clinical Trials Market in 2022.
Recent Developments
- In August 2022, to prevent invasive pneumococcaldisease (IPD) brought on by the 20 Streptococcus pneumoniae (pneumococcus)serotypes contained in the vaccine for the paediatric population, Pfizer Inc.recently announced positive top-line results from its pivotal U.S. Phase 3study (NCT04382326) in infants. The study's two co-primary goals werenon-inferiority (NI) of the proportion of participants with predefinedserotype-specific immunoglobin G (IgG) concentrations after Dose 3 and NI ofIgG geometric mean concentrations (GMCs) after Dose 4, which were related toimmunogenicity responses one month after the third and fourth doses of thefour-dose vaccination series, respectively. After Dose 4, all 20 serotypesachieved the co-primary goal of NI of IgG GMCs. Fourteen of the 20 serotypesachieved noninferiority for the primary secondary objective of IgG GMCs afterDose 3, and all serotypes achieved noninferiority for the co-primary objectiveof NI of the percentage of participants with predefined IgG levels after Dose 3(two serotypes missed by a wider margin and four narrowly missed). In this20-valent vaccine candidate, all 20 serotypes produced strong functionalresponses (OPA) and increases in antibody responses after Dose 4. The sum ofthe findings supports the potential benefit of all 20 serotypes.
- In July2022, A Phase 3 trial evaluating the investigational use of Dupixent®(dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE)met its primary endpoint of histological disease remission at 16 weeks withboth higher and lower dose weight-tiered regimens, according to a press releasefrom Regeneron Pharmaceuticals, Inc., and Sanofi. For kids under the age of 12,there are no recognised treatments for EoE. EoE is a chronic inflammatory condition that harms the oesophagus andimpairs its functionality. Dupixent's effects on adults and kids with EoE showthat IL-4 and IL-13 are important regulators of the type 2 inflammation thatunderlies this condition. Children with eosinophilic esophagitis frequentlyhave acid reflux, vomiting, stomach pain, difficulty swallowing, and a failureto thrive. These symptoms may have an adverse effect on growth and developmentas well as lead to a dread of food that may last into adulthood.
Key Market Players
- Bristol-MyersSquibb Company
- Charles River Laboratories International Inc.
- Covance Inc.
- GlaxoSmithKline plc
- ICON plc
- IQVIA Inc.
- Novartis AG
- Pfizer, Inc.
- Pharmaceutical Product Development, LLC
- Syneos Health Inc.
- Paidion Research, Inc.
- The EmmesCompany, LLC
| By Phase | By Study Design | By Therapeutic Area | By Region |
| · Phase I · Phase II · Phase III · Phase IV | · Treatment Studies · Observational Studies | · Respiratory Disease · Infectious Diseases Oncology · Diabetes · Other Therapeutic Areas | · North America · Asia-Pacific · Europe · South America · Middle East & Africa |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy